K Lance Gould1,2, Linh Bui3, Danai Kitkungvan3, Monica B Patel3. 1. Weatherhead PET Center For Preventing and Reversing Atherosclerosis, Division of Cardiology, Department of Medicine, McGovern Medial Medical School, University of Texas, and Memorial Hermann Hospital, Houston, TX, USA. k.lance.gould@uth.tmc.edu. 2. Weatherhead PET Center For Preventing and Reversing Atherosclerosis, McGovern Medical School, University of Texas Health Science Center at Houston, 6431 Fannin St., Room MSB 4.256, Houston, TX, 77030, USA. k.lance.gould@uth.tmc.edu. 3. Division of Cardiology, McGovern Medical School, Houston, TX, USA.
Abstract
PURPOSE OF REVIEW: The COURAGE and ISCHEMIA trials showed no reduced mortality after revascularization compared to medical treatment. Is this lack of benefit due to revascularization having no benefit regardless of CAD severity or to suboptimal patient selection due to non-quantitative cardiac imaging? RECENT FINDINGS: Comprehensive, integrated, myocardial perfusion quantified by regional pixel distribution of coronary flow capacity (CFC) is the final common expression of objective CAD severity for which revascularization reduces mortality. Current lack of revascularization benefit derives from narrow thinking focused on measuring one isolated aspect of coronary characteristics, such as angiogram stenosis, its fractional flow reserve (FFR), anatomic FFR simulations, relative stress imaging, absolute stress ml/min/g or coronary flow reserve (CFR) alone, or even more narrowly on global CFR or fixed regions of interest in assumed coronary artery distributions, or in arbitrary 17 segments on bull's-eye displays, rather than regional pixel distribution of perfusion metrics as they actually are in an individual. Comprehensive integration of all quantitative perfusion metrics per regional pixel into coronary flow capacity guides artery-specific interventions for reduced mortality in non-acute CAD but requires addressing the methodologic questions in the title.
PURPOSE OF REVIEW: The COURAGE and ISCHEMIA trials showed no reduced mortality after revascularization compared to medical treatment. Is this lack of benefit due to revascularization having no benefit regardless of CAD severity or to suboptimal patient selection due to non-quantitative cardiac imaging? RECENT FINDINGS: Comprehensive, integrated, myocardial perfusion quantified by regional pixel distribution of coronary flow capacity (CFC) is the final common expression of objective CAD severity for which revascularization reduces mortality. Current lack of revascularization benefit derives from narrow thinking focused on measuring one isolated aspect of coronary characteristics, such as angiogram stenosis, its fractional flow reserve (FFR), anatomic FFR simulations, relative stress imaging, absolute stress ml/min/g or coronary flow reserve (CFR) alone, or even more narrowly on global CFR or fixed regions of interest in assumed coronary artery distributions, or in arbitrary 17 segments on bull's-eye displays, rather than regional pixel distribution of perfusion metrics as they actually are in an individual. Comprehensive integration of all quantitative perfusion metrics per regional pixel into coronary flow capacity guides artery-specific interventions for reduced mortality in non-acute CAD but requires addressing the methodologic questions in the title.
Authors: Krishna K Patel; John A Spertus; Paul S Chan; Brett W Sperry; Randall C Thompson; Firas Al Badarin; Kevin F Kennedy; James A Case; Staci Courter; Ibrahim M Saeed; A Iain McGhie; Timothy M Bateman Journal: J Am Coll Cardiol Date: 2019-10-01 Impact factor: 24.094
Authors: Danai Kitkungvan; Dejian Lai; Hongjian Zhu; Amanda E Roby; Nils P Johnson; Derek D Steptoe; Monica B Patel; Richard Kirkeeide; K Lance Gould Journal: Circ Cardiovasc Imaging Date: 2017-02 Impact factor: 7.792
Authors: Viviany R Taqueti; Rory Hachamovitch; Venkatesh L Murthy; Masanao Naya; Courtney R Foster; Jon Hainer; Sharmila Dorbala; Ron Blankstein; Marcelo F Di Carli Journal: Circulation Date: 2014-11-16 Impact factor: 29.690
Authors: Ibrahim Danad; Pieter G Raijmakers; Roel S Driessen; Jonathon Leipsic; Rekha Raju; Chris Naoum; Juhani Knuuti; Maija Mäki; Richard S Underwood; James K Min; Kimberly Elmore; Wynand J Stuijfzand; Niels van Royen; Igor I Tulevski; Aernout G Somsen; Marc C Huisman; Arthur A van Lingen; Martijn W Heymans; Peter M van de Ven; Cornelis van Kuijk; Adriaan A Lammertsma; Albert C van Rossum; Paul Knaapen Journal: JAMA Cardiol Date: 2017-10-01 Impact factor: 14.676
Authors: Ankur Gupta; Viviany R Taqueti; Tim P van de Hoef; Navkaranbir S Bajaj; Paco E Bravo; Venkatesh L Murthy; Michael T Osborne; Sara B Seidelmann; Tomas Vita; Courtney F Bibbo; Meagan Harrington; Jon Hainer; Ornella Rimoldi; Sharmila Dorbala; Deepak L Bhatt; Ron Blankstein; Paolo G Camici; Marcelo F Di Carli Journal: Circulation Date: 2017-09-01 Impact factor: 29.690
Authors: Krishna K Patel; John A Spertus; Paul S Chan; Brett W Sperry; Firas Al Badarin; Kevin F Kennedy; Randall C Thompson; James A Case; A Iain McGhie; Timothy M Bateman Journal: Eur Heart J Date: 2020-02-01 Impact factor: 29.983
Authors: Robert M Bober; Richard V Milani; Ahmet A Oktay; Fahad Javed; Nichole M Polin; Daniel P Morin Journal: Eur J Nucl Med Mol Imaging Date: 2019-02-26 Impact factor: 9.236
Authors: K Lance Gould; Linh Bui; Danai Kitkungvan; Tinsu Pan; Amanda E Roby; Tung T Nguyen; Nils P Johnson Journal: J Nucl Cardiol Date: 2020-02-24 Impact factor: 5.952